FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in ...

FDA expands approval for Zoryve cream 0.3% to children with psoriasis as young as 2 years

The FDA approved Zoryve cream 0.3% for the treatment of plaque psoriasis in children as young as 2 years, Arcutis announced in a press release. Roflumilast (Zoryve, Arcutis) cream 0.3%, a phosphodiesterase-4 inhibitor, is already FDA-approved for children 6 years and older. The expanded indication gives caregivers a once-daily, steroid-free topical for younger children with psoriasis, including

FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in ...

ZORYVE cream 0.3% is the first once-daily, non-steroidal therapy approved for children with plaque psoriasis as young as 2 years of ageZORYVE cream 0.3% is safe, effective, and well-tolerated for use anywhere on the body with no restrictions on duration…

FDA Expands Approval of Roflumilast Cream (Zoryve) to Younger Children with Plaque Psoriasis

As reported on Healio, the U.S. Food and Drug Administration has broadened the indication for roflumilast cream 0.3% (Zoryve, Arcutis), allowing its use in children with plaque psoriasis as young as 2 years of age. This decision introduces the first nonsteroidal topical prescription therapy for this patient population, addressing a longstanding gap in pediatric dermatology […]

FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children as Young as Age 2